Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To register, simply click the Register button at the top right.
i meant to post the following on this post but did so by mistake in another thread.
There has been new correspondance in PNAS for Naviaux et al:
A commentary from Roerick et al. (Including van der Meer) has been published here
There is a new reply from Dr Naviaux to their comment on the PNAS website. You can access the response here.
MEDICAL SCIENCES Correction for “Metabolic features of chronic fatigue syndrome,” by Robert K. Naviaux, Jane C. Naviaux, Kefeng Li, A. Taylor Bright, William A. Alaynick, Lin Wang, Asha Baxter, Neil Nathan, Wayne Anderson, and Eric Gordon, which appeared in issue 37, September 13, 2016, of Proc Natl Acad Sci USA(113:E5472–E5480; first published August 29, 2016; 10.1073/pnas.1607571113).
The editor, R.W.D., wishes to note that he has consulted with R.K.N. with respect to R.W.D.’s son’s metabolism and with E.G. with respect to R.W.D.’s son’s care. These consultations played no role in the work or the editing of this paper. R.W.D.’s son was not a subject in this study. After this research study was completed, written, and edited, R.W.D., as chair of the Open Medicine Foundation (OMF) Scientific Advisory Board, asked R.K.N. to join the board and began collaborating with him and E.G. on follow-up studies related to this work. Thus, R.W.D. now has a professional relationship with R.K.N. and E.G. The OMF provided a grant to R.K.N. to support the follow-up studies. The OMF and R.W.D. played no role in the work described in this paper.
My uneducated guess is that this chronically reduced metabolic rate at the cellular level is not simply a case of being stuck in the "low" position. Rather, it's driven by another chronic process that won't resolve, like an infection or autoimmunity, or an alteration in the microbiome (perhaps initiated by an infection), and one or more of those things is leading to chaos at the cellular level. Fix the problem upstream and, hopefully, the cellular metabolism will return to normal.
At the moment, at least, I think the real importance of this finding is in its diagnostic value as a biomarker. That in itself is HUGE.
We expect to publish the study sometime in late 2017.
Yes I took it that they edited the title to reflect the delay. I remember the fall being the original timescale and then remember seeing the late fall being an update.@John Mac It says 2018 in the title but still says 2017 in the body of the article.
Just wondering if any of the ME CFS researchers have used this method?
Hi...see study in japan from 2014...however small sized study..they used PK11195 during Petscan..neuroinflamm. was reported.
Now, sept 2017, they started on replicating finding in bigger cohort of me cfs patients. And they us [11C]PBR28.